CytoDyn Inc.
Last verified 2026-05-13. JSON
| Total raised | $18.6M |
|---|---|
| Latest round | Funding round, $18.6M, 2026-05-11 |
| Founded | unknown |
| Headquarters | Vancouver, WA |
| Industry | pharmaceuticals |
| Stage | unknown |
| Website | cytodyn.com |
Clinical-stage biotechnology developing leronlimab, a humanized monoclonal antibody targeting CCR5 for solid-tumor oncology and immunologic indications.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2026-05-11 | Funding round | $18.6M | undisclosed |
Detected tech stack
Apache HTTP Server, apache
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $18.6M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Total raised $18.6M | sourced | SEC EDGAR named as publisher. Document, retrieved 2026-09-25. |
| Company existence | self-reported | cytodyn.com, read 2026-05-13 |
| Description | self-reported | cytodyn.com, read 2026-05-13 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $18.6M, 2026-05-11 → Funding round, $18.6M, 2026-05-11, SEC EDGAR, document, retrieved 2026-09-25 | Latest round | seed, $18.6M, 2026-05-11 → Funding round, $18.6M, 2026-05-11 | SEC EDGAR, document, retrieved 2026-09-25 |
| 2026-09-25Round: attributed → sourced, SEC EDGAR, document, retrieved 2026-09-25 | Round | attributed → sourced | SEC EDGAR, document, retrieved 2026-09-25 |
Records begin 2026-09-24. All changes